Foghorn Therapeutics Stock Revenue Per Share
| FHTX Stock | USD 4.48 0.10 2.18% |
Foghorn Therapeutics fundamentals help investors to digest information that contributes to Foghorn Therapeutics' financial success or failures. It also enables traders to predict the movement of Foghorn Stock. The fundamental analysis module provides a way to measure Foghorn Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Foghorn Therapeutics stock.
Foghorn |
Foghorn Therapeutics Company Revenue Per Share Analysis
Foghorn Therapeutics' Revenue per Share is a ratio of total revenue earned per one share of common stock over a single fiscal year. It is calculated by dividing sales revenue earned over 12 months by the average number of outstanding shares. Revenue used in the calculation of this ratio is typically recorded when cash or cash equivalents are exchanged for services or goods.
Revenue per share does not take into account any of company expenses and is helpful only when comparing relative sale figures within a given industry.
| Competition |
Based on the latest financial disclosure, Foghorn Therapeutics has a Revenue Per Share of 0.0 times. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Foghorn Revenue Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Foghorn Therapeutics' direct or indirect competition against its Revenue Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Foghorn Therapeutics could also be used in its relative valuation, which is a method of valuing Foghorn Therapeutics by comparing valuation metrics of similar companies.Foghorn Therapeutics is currently under evaluation in revenue per share category among its peers.
Foghorn Fundamentals
| Return On Equity | -4.7 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (8.41) % | ||||
| Current Valuation | 40.3 M | ||||
| Shares Outstanding | 55.61 M | ||||
| Shares Owned By Insiders | 18.97 % | ||||
| Shares Owned By Institutions | 72.60 % | ||||
| Number Of Shares Shorted | 965.32 K | ||||
| Price To Book | 10.71 X | ||||
| Price To Sales | 11.27 X | ||||
| Revenue | 22.6 M | ||||
| Gross Profit | (71.93 M) | ||||
| EBITDA | (97.17 M) | ||||
| Net Income | (86.62 M) | ||||
| Cash And Equivalents | 373.5 M | ||||
| Cash Per Share | 8.94 X | ||||
| Total Debt | 37.13 M | ||||
| Debt To Equity | 2.19 % | ||||
| Current Ratio | 6.84 X | ||||
| Book Value Per Share | (0.82) X | ||||
| Cash Flow From Operations | (100.41 M) | ||||
| Short Ratio | 6.16 X | ||||
| Earnings Per Share | (1.58) X | ||||
| Target Price | 11.5 | ||||
| Number Of Employees | 112 | ||||
| Beta | 3.13 | ||||
| Market Capitalization | 254.7 M | ||||
| Total Asset | 283.98 M | ||||
| Retained Earnings | (558.18 M) | ||||
| Working Capital | 182.61 M | ||||
| Net Asset | 283.98 M |
About Foghorn Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Foghorn Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Foghorn Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Foghorn Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.